Navigation Links
QRxPharma Doses First Patients in Phase III Clinical Trial Program for its 'Dual Opioid' Pain Therapy
Date:11/26/2007

First study to focus on acute, post-surgical pain, with a follow-on safety extension trial to begin in late-2007

SYDNEY, Australia, Nov. 26 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX) announced today that a number of patients have been treated in the first of several clinical studies to be conducted as part of the Phase III development program for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy.

The initial clinical trial is a double-blind, placebo-controlled study designed to compare the efficacy and safety of four different dosage strengths of Q8003IR vs. placebo in a post-surgery, acute pain setting. The study is being conducted at 8 US clinical research sites and is targeted to enroll 250 patients experiencing moderate to severe pain following a scheduled surgical procedure (bunionectomy).

"Initiation of this Phase III clinical trial program not only demonstrates the Company's ability to deliver on its development milestones for Q8003IR in terms of budget and time-line projections, but also represents a significant step forward towards our goal of commercializing our first dual-opioid pain therapy in 2010," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.

The primary clinical endpoints for this acute, post-surgery pain study focus on pain relief and pain intensity scores vs. placebo over the first 48 hours post-surgery. Secondary endpoints include: (1) efficacy relating to the time to onset of analgesia and the duration of effect from a single oral dose; and (2) safety as measured by the incidence and intensity of opioid-related adverse events. A safety extension trial will immediately follow patient enrollment in this first trial to begin capturing longer-term patient safety data in support of our planned future New Drug Application (NDA) data submission package for Q8003IR.

Q8003IR is a patent-protected, immediate release dual-opioid product that synergistically combines sub-analgesic doses of oxycodone and morphine. Several clinical trials to date have shown that this unique, dual-opioid combination can achieve equal or better analgesic pain relief at materially lower doses than the active opioid comparator while simultaneously reducing side effects (eg: less nausea, vomiting, respiratory depression, constipation and sedation).

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, improved safety and patient outcomes, and greater market value for direct commercialization in the US as well as potential for strategic partnerships abroad. QRxPharma's lead compound, Q8003IR, began its Phase III development program in November 2007. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: http://www.QRxPharma.com.


'/>"/>
SOURCE QRxPharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
3. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... COUNTY, Calif. , May 3, 2016  While you may be familiar with watching a ... resolution , also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a ... manufacturer of innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... pay $55 million to a woman who says its ... court awarded Gloria Ristesund $5 million in ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... accusations against the company. In February, the same court ...
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: NTEC ... the appointment of Pnina Strauss-Levy as Vice ... has 15 years of experience in clinical research and ... having supported the advancement of several products through the ... the United States and Europe ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 2016 , ... Healing Cancer in This Century is a Summit ... recovery and is offered by creator and visionary Carlos Caridad. Healing Cancer In ... considering medical and healing modalities of the fields of Integrative, Alternative, Energetic, Holistic ...
(Date:5/3/2016)... ... May 03, 2016 , ... California health startup Pegara announced ... helps people assess their risk of developing Alzheimer’s disease. Using a questionnaire based ... “Risk Reduction Score™” that summarizes how their lifestyle choices may affect their chances ...
(Date:5/3/2016)... ... 03, 2016 , ... With the opioid epidemic now at the forefront, attention ... use. Alcohol and its misuse causes long-term consequences for all aspects of society, ... in those 65 years and older. In addition, there is the long term ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... DNA or RNA from a random library of sequences depending on their attraction ... or diagnostic agents. SELEX selection is commonly performed using filters, panning, or affinity ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... director Joe Ferrazano to serve in the newly created position of executive vice ... the agency’s creative efforts in the Chicago and LA offices. He reports to ...
Breaking Medicine News(10 mins):